
Marina Baretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7240763/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356
2	An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 2019, 19, 639-650.	12.8	139
3	Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 2015, 47, 884-890.	0.4	59
4	The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 2018, 42, 530-547.	1.0	53
5	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 2017, 28, 555-561.	0.6	43
6	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 2016, 8, 1363-1369.	1.0	34
7	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
8	Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Annals of Translational Medicine, 2015, 3, 83.	0.7	25
9	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	0.9	19
10	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 2022, , .	1.5	19
11	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 2018, 17, e489-e498.	1.0	16
12	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clinical Epigenetics, 2021, 13, 25.	1.8	11
13	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. Journal of Clinical Investigation, 2021, 131, .	3.9	11
14	The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 585-589.	0.5	10
15	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Oncolmmunology, 2021, 10, 2001159.	2.1	10
16	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. Cancer Biology and Therapy, 2018, 19, 659-663.	1.5	9
17	Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 2022, 40, 252-254.	7.7	9
18	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5

MARINA BARETTI

#	Article	IF	CITATIONS
19	Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 0, 2, 18-18.	1.2	5
20	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 2021, 14, 954-963.	1.5	5
21	Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 2021, 28, 107327482110099.	0.7	4
22	Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma Journal of Clinical Oncology, 2018, 36, TPS4151-TPS4151.	0.8	4
23	Precision Cancer Trials With Immunomodulatory Agents. Cancer Journal (Sudbury, Mass), 2019, 25, 287-295.	1.0	3
24	Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer Journal of Clinical Oncology, 2019, 37, 570-570.	0.8	0
25	The impact of the immune microenvironment in patients with GEP-NETs Journal of Clinical Oncology, 2019, 37, 267-267.	0.8	0